Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

NCT06228482 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT06228482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06228482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Recruiting
Start date
January 22, 2024
Completion date
January 31, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nonsmall cell lung cancer